Search

Displaying results 9371 - 9380 of 9431 in total
  1. Drug

    AB-207

    go.drugbank.com/drugs/DB22801
    Investigational

    AB-207 is under investigation in clinical trial NCT06456073 (E-CEL UVEC Treatment for Anal Fissures).

    Synonyms: E-CEL UVE, E-CEL UVEC cells
  2. Drug

    Anti-CD7 CAR-T

    go.drugbank.com/drugs/DB23322
    Investigational

    CD7 CAR-T is a biologic drug. CD7 CAR-T is under investigation in clinical trial NCT07117305 (CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation).

    Synonyms: CD7 CAR T, CD7 CAR-T
  3. Drug

    ARI-0001

    go.drugbank.com/drugs/DB30635
    Investigational

    ARI-0001 is under investigation in clinical trial NCT05641428 (Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL).

  4. Drug

    Palmitic Acid

    go.drugbank.com/drugs/DB03796
    ApprovedInvestigational

    A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.

    Mixtures: Huile D'onagre Vitamin E
  5. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  6. Drug

    Gimatecan

    go.drugbank.com/drugs/DB06721
    Investigational

    Gimatecan is an orally available 7-t-butoxyiminomethyl-substituted lipophilic camptothecin derivative.

    Synonyms: (4S)-11-[(E)-(tert-butoxyimino)methyl]-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, (4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3',4':6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime
  7. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  8. Drug

    PHE885

    go.drugbank.com/drugs/DB18123
    Investigational

    PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.

  9. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

  10. Drug

    CT120

    go.drugbank.com/drugs/DB18181
    Investigational

    CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.